Capricor Therapeutics Inc CAPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Trading Information
- Previous Close Price
- $8.87
- Day Range
- $8.98–11.23
- 52-Week Range
- $0.00–40.37
- Bid/Ask
- $11.01 / $11.05
- Shares Outstanding
- 58.14M
- Market Cap
- $652.32M
- Volume/Avg
- 10M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 231
- Website
- https://www.capricor.com
Valuation
Metric | CAPR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CAPR |
|---|---|
Quick Ratio | 6.61 |
Current Ratio | 6.77 |
Interest Coverage | — |
Quick Ratio
CAPR
Profitability
Metric | CAPR |
|---|---|
Return on Assets (Normalized) | −43.46% |
Return on Equity (Normalized) | −58.29% |
Return on Invested Capital (Normalized) | −48.49% |
Return on Assets
CAPR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|?cl!Q^ | LOCK|l#w@b | $139B | |||
| Moderna Inc MRNA | LOCK|&DD^<^^ | LOCK|rJ | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|t>c@Dq@ | LOCK|@@tK | $99B | |||
| argenx SE ADR ARGX | LOCK|m^fNTg | LOCK|@N# | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|PS$^Zm | LOCK|T#@ | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|V$swk^#H | LOCK|hv?! | $31B | |||
| Incyte Corp INCY | LOCK|Q#T$@% | LOCK|P%# | $25B | |||
| BioNTech SE ADR BNTX | LOCK|pc?R%s | LOCK|WV | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|FxPL%@ | LOCK|#<t% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>RstP&# | LOCK|$< | $16B |
United States